BACKGROUND AND OBJECTIVE: Hepatitis B virus (HBV) reactivation is a major risk factor for hepatic dysfunction, acute or chronic hepatitis, cirrhosis, or hepatocellular carcinoma after kidney transplantation (KTP). The present article summarizes some of published articles about prevention of HBV reactivation in renal transplant recipients METHODS: Many articles published in English language as f...

BACKGROUND Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment. AIM To investigate predictive factors of response, using a quantitative method with high sensitivity. METHODS We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at ...

There are limited data describing the concentrations of zidovudine, lamivudine, and nevirapine in nursing infants as a result of transfer via breast milk. The Kisumu Breastfeeding Study is a phase IIb open-label trial of prenatal, intrapartum, and postpartum maternal treatment with zidovudine, lamivudine, and nevirapine from 34 weeks of gestation to 6 months postpartum. In a pharmacokinetic sub...

BACKGROUND Long-term lamivudine therapy, despite its initial effectiveness against hepatitis B virus (HBV), is associated with the emergence of drug resistance mutations in polymerase protein. OBJECTIVES The aim of the present study was to determine the prevalence of precore and lamivudine drug resistance mutations in lamivudine treated patients with chronic B hepatitis. PATIENTS AND METHOD...

In this study, we were synthesized Fe3O4@LDH@Lamivudine and characterized by FT-IR spectroscopy,XRD and TEM. The interaction of this nanoparticle with CT-DNA was investigated by viscosity, circulardichroism (CD), Uv-Visible and fluorescence spectroscopy. Among all nanocarriers which applied as drugdelivery vectors, layered double hydroxides (LDHs) with exchangeable anions in t...

The relation between HBV and glomerulonephritis including membranous and mesengio-proliferative glomerulonephritis has been well documented.1 However, only six cases of HBV associated focal segmental glomerulosclerosis (FSGS) were reported previously.2-5 Reduction of HBV DNA titers is important for remission of HBV-associated glomerulopathies. We herein represent a case of HBV-associated FSGS w...

BACKGROUND Many HIV-infected patients in sub-Saharan Africa are not routinely screened for hepatitis B virus (HBV) infection and are on antiretroviral therapy (ART) regimens containing only lamivudine as anti-HBV active drug. METHODS In 2009-2011, we screened for hepatitis B surface antigen (HBsAg) in 2820 HIV-infected adults patients at the Mbarara Hospital Uganda and investigated risk facto...

The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naïve patients with HBeAg positive chronic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who received 30 mg of clevudine once daily (n=53) or 100 mg of lamivudine once daily (n=63) for 48 weeks, were included. At week 48, clevudine therapy...

BACKGROUND The evolution of drug-resistant viruses challenges the management of human immunodeficiency virus (HIV) infections. Understanding this evolutionary process is important for the design of effective therapeutic strategies. METHODS We used mutagenetic trees, a family of probabilistic graphical models, to describe the accumulation of resistance-associated mutations in the viral genome....

Despite a decline in cases of acute hepatitis B and the low hepatitis B virus (HBV) chronicity rates in adults, still some patients progress to HBV-related fulminant liver failure. In this review, we discuss treatment options that may prevent the progression of severe acute hepatitis B to fulminant liver failure and death. In severe acute HBV with prolonged prothrombin time and increased biliru...